A Phase II study of ONO-4538 in patients with relapsed or metastatic malignant melanoma

Trial Profile

A Phase II study of ONO-4538 in patients with relapsed or metastatic malignant melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Dec 2016

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ono Pharmaceutical
  • Most Recent Events

    • 25 Nov 2016 Status changed from active, no longer recruiting to completed.
    • 13 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top